Clinical trials: Oral Anticoagulant
Atrial Fibrillation, Stroke
DOAC in Chinese Patients With Atrial Fibrillation
Direct oral anticoagulants (DOACs) have emerged as safe and efficacious ischemic stroke prophylaxis for non-valvular atrial fibrillation (NVAF).
- Conditions
- Atrial Fibrillation, Stroke, Stroke, Acute, Brain Diseases
- Trial name
- DOAC-REAL (NCT05378035)
- Testing
- Blood Tests
- Where
- Hong Kong
- Volunteers
- 427 people
- Sponsor
- Chinese University of Hong Kong
Atrial Fibrillation
The Effectiveness of Interactive Nursing Education Program Through Health Belief Model Based and Informative Technology-assisted on Atrial Fibrillation Patients Receiving Oral Anticoagulant
This study examined patients on taking oral anticoagulants (OACs) are often prescribed for Atrial fibrillation (AFib) to determine the effectiveness of a multiple interactive health education program, which was developed based on…
- Trial name
- NCT05145634
- Testing
- Patient education related oral anticoagulants (OACs)
- Volunteers
- 150 people
- Sponsor
- Chang Gung Memorial Hospital
Direct Oral Anticoagulants (DOACs), Femoral Fractures
Impact of Treatment With Oral Anticoagulants of Patients With Fractures of the Upper End of the Femur
In 2023, oral anticoagulant treatments (anti Xa: apixaban , rivaroxaban, etc.) are tending to replace anti vitamin K treatments in many medical indications. Their prescription is increasing rapidly in the elderly.
- Conditions
- Direct Oral Anticoagulants (DOACs), Femoral Fractures, Surgery
- Trial name
- ANTI_XA AOD (NCT06382584)
- Testing
- Femoral fracture surgery
- Where
- France
- Volunteers
- 610 people
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
Atrial Fibrillation
Decentralized Trial in Atrial Fibrillation Patients
The purpose of this study is to validate an approach to decentralize, or virtualize, the clinical trial experience for enrolled subjects, through the coordinated use of multiple digital health and telehealth technologies.
- Trial name
- DeTAP (NCT04471623)
- Testing
- Use of DeTAP App and Home Devices
- Where
- United States
- Volunteers
- 102 people
- Sponsor
- Stanford University
Hematoma
Strategy of Continued Versus Interrupted Novel Oral Anti-coagulant at Time of Device Surgery in Patients With Moderate to High Risk of Arterial Thromboembolic Events
The purpose of this study is to determine the best strategy to manage novel oral anti-coagulants (NOACs) at the time of pacemaker or defibrillator surgery.
- Trial name
- BRUISECONTROL2 (NCT01675076)
- Testing
- Dabigatran, Rivaroxaban, Apixaban
- Where
- 15 sites in Canada, Israel
- Volunteers
- 663 people
- Sponsor
- Ottawa Heart Institute Research Corporation
Anticoagulant Drugs, Diabetes Mellitus, Type 2
Effect of an Electronic Reminder System on Direct Oral Anticoagulant and Oral Diabetes Medication Adherence
In this study, the effect of an electronic device attached to a push through pill package and a smart phone application on chronic disease medication adherence is studied.
- Trial name
- NCT03753568
- Testing
- Electronic medicine reminder system
- Where
- Finland
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Helsinki University Central Hospital
Coronary Artery Disease, Percutaneous Coronary Intervention
NOAC Therapy Guided by PARIS Risk Score and D-dimer in Patients With ACS After PCI
The goal of this clinical trial is to compare short-term Triple Antithrombotic Therapy (DAPT + Rivaroxaban) followed by DAPT with standard DAPT in selected ACS patients with high ischemic risk.
- Conditions
- Coronary Artery Disease, Percutaneous Coronary Intervention, Acute Coronary Syndrome
- Trial name
- NCT05638867
- Testing
- Aspirin + Clopidogrel + Rivaroxaban, Aspirin + Clopidogrel
- Where
- China
- Volunteers
- 3,944 people
- Sponsor
- China National Center for Cardiovascular Diseases
Benign Prostatic Hyperplasia, Anticoagulant Adverse Reaction
Stop or Ongoing Oral Anticoagulation in Patients Undergoing Pvp (SOAP)
Benign prostatic hyperplasia (BPH) is a very common pathology of the aging man with an incidence that rises from 40% in men aged 50 to 60 years to 90% in men over 80 years.
- Trial name
- SOAP (NCT03297281)
- Testing
- Maintenance of OAC in surgery of BPH by PVP., Discontinuation of OAC in surgery of BPH by PVP.
- Where
- France
- Volunteers
- 389 people
- Sponsor
- Clinique Pasteur
Thrombotic Stroke, Atrial Fibrillation and Flutter
ReAl-life Multicentre Survey Evaluating Stroke Prevention Strategies (RAMSES)
The aim of this study is to evaluate the present status of stroke prevention strategies in patients with non-valvular atrial fibrillation (NVAF).
- Trial name
- RAMSES (NCT02344901)
- Where
- 62 sites in Turkey (Türkiye)
- Volunteers
- 6,273 people
- Sponsor
- Muğla Sıtkı Koçman University
Atrial Fibrillation (AF)
Gastroprotective Efficacy of Rebamipide in Patients With Atrial Fibrillation Treated With DOACs
The goal of this clinical trial is to learn if Rebamipide effective in gastroprotection in patients with atrial fibrillation who are treated with Direct Oral Anticoagulants (DOACs).
- Trial name
- REGATA (NCT07354230)
- Testing
- Rebamipide 100mg, Pantoprazole
- Where
- Russia
- Volunteers
- 210 people
- Sponsor
- Pirogov Russian National Research Medical University
Antiphospholipid Syndrome (APS), Cohort Study
DOAC Versus VKA in Patients With Non-high-risk APS : Prospective Cohort Study
Antiphospholipid syndrome (APS) is a thrombotic disease requiring prolonged anticoagulation. Direct oral anticoagulants (DOACs) are indicated as 1st-line therapy in venous thrombosis, compared with VKAs, due to their easier…
- Conditions
- Antiphospholipid Syndrome (APS), Cohort Study, Thrombotic and Bleeding Events
- Trial name
- DOWAPS (NCT06884384)
- Testing
- Additional blood collection during routine blood sampling at the inclusion (33.9 ml) and at the thrombotic recurrence (between 3.5 and 5 ml), Completion of a questionnaire on compliance with anticoagulant treatment, Completion of a questionnaire on satisfaction with treatment anticoagulant
- Where
- 13 sites in France
- Volunteers
- 310 people
- Sponsor
- Central Hospital, Nancy, France
Atrial Fibrillation
Therapeutic Strategy with Direct Oral Anticoagulants and Antiaggregant Drugs in Ischemic Heart Disease
The study aims to depict the actual prescription patterns employed in clinical practice of patients affected by non-valvular atrial fibrillation undergoing percutaneous coronary intervention (i.e.
- Trial name
- PRODOAC (NCT06239402)
- Testing
- Observation
- Where
- Italy
- Volunteers
- 394 people
- Sponsor
- Istituti Clinici Scientifici Maugeri SpA
AOD Prescription
Impact of Renal Function Availability to Community Pharmacist for Dispensing Direct Oral Anticoagulant in Ambulatory Patients on Bleeding Occurrence
The use of direct oral anticoagulants (AODs) in the prevention and treatment of thromboembolic diseases is increasing, with a favorable benefit/risk balance and improved quality of life for patients.
- Trial name
- Hemorrag-IR (NCT06739603)
- Testing
- pharmaceutical analysis
- Volunteers
- 1,920 people
- Sponsor
- Université de Reims Champagne-Ardenne
Bleeding
A Study in Participants With Acute Major Bleeding to Evaluate the Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Direct and Indirect Oral Anticoagulants (Extension Study)
The purpose of this study was to evaluate the hemostatic efficacy of andexanet alfa (andexanet) in participants receiving a factor Xa (FXa) inhibitor (apixaban, rivaroxaban, edoxaban, enoxaparin) who were experiencing an acute…
- Trial name
- NCT02329327
- Testing
- Andexanet
- Where
- 87 sites in United States, Belgium and 7 more
- Volunteers
- 479 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Bleeding
A Multifaceted Intervention to Improve Bleeding Management Among Patients Using Oral Anticoagulants (IMPACT-BLEEDING)
Prospective, cluster randomized trial including expected 168 patients with chronic use of oral anticoagulation (OAC) suffering major bleeding.
- Trial name
- NCT06575517
- Sponsor
- AstraZeneca
Novel Oral Anticoagulants, NOACs
Imapct of bioMarkers on Pharmacodynamics and Bleeding Risk of Direct Oral AntiCoagulants and Ticagrelor Study II
Individual differences in drug efficacy and adverse reactions are common in the clinical application of drugs. Individual differences are caused by many factors, among which genetic factors account for more than 20%.
- Conditions
- Novel Oral Anticoagulants, NOACs, Rivaroxaban, Apixaban
- Trial name
- NCT05764356
- Testing
- Detection of genotype and RNA profile in platelet and white blood cell, Indicators test related to coagulation function, Indicators test related to platelet function
- Where
- 6 sites in China
- Volunteers
- 2,000 people
- Sponsor
- Peking University First Hospital
Anticoagulants and Bleeding Disorders, Surgery
Oral Surgery in Patients Taking Direct Oral Anticoagulants
This study evaluates the incidence of postoperative bleeding after oral surgical procedures in patients taking direct oral anticoagulants and in patients taking vitamin K antagonists.
- Conditions
- Anticoagulants and Bleeding Disorders, Surgery, Postoperative Hemorrhage, Dentoalveolar Haemorrhage
- Trial name
- OSDOA (NCT04505475)
- Testing
- Oral surgical procedure followed by local hemostatic measures (insertion of gelatine sponge and wound suturing)
- Where
- Serbia
- Volunteers
- 82 people
- Sponsor
- University of Novi Sad
Atrial Fibrillation
This Study Observes the Usage of Non-vitamin K Antagonist Oral Anticoagulants (NOACs) in Elderly Patients With a Heart Rhythm Disorder in Spain
This is an observational, multicenter and cross-sectional study in Non-valvular atrial fibrillation (NVAF) elderly patients currently on Non-vitamin K antagonist oral anticoagulant (NOAC) treatment for their stroke prevention.
- Trial name
- NCT03993119
- Testing
- Non-vitamin K antagonist oral anticoagulant
- Where
- 45 sites in Spain
- Volunteers
- 500 people
- Sponsor
- Boehringer Ingelheim
Cardiopathy, Chagas Disease
Outcomes of an Anticoagulation Clinic in an University Hospital
A clinical trial designed to compare the oral anticoagulation control obtained by an anticoagulation clinic and the usual medical care in Chagas and Non-Chagas disease patients.
- Conditions
- Cardiopathy, Chagas Disease, Hemorrhage, Thrombosis
- Trial name
- NCT01006486
- Testing
- Anticoagulation clinic, Standard anticoagulation care
- Where
- Brazil
- Volunteers
- 280 people
- Sponsor
- Federal University of Minas Gerais
Ischemic Stroke, Oral Anticoagulation
Advancing Knowledge in Ischemic Stroke Patients on Oral Anticoagulants
The Advancing knowledge in ischemic Stroke PatiEnts on oRal Anticoagulants (ASPERA) study aims to investigate characteristics of ischemic stroke cases occurring in patients on oral anticoagulation for atrial fibrillation (AF) or…
- Conditions
- Ischemic Stroke, Oral Anticoagulation, Atrial Fibrillation (AF), Outcome Assessment
- Trial name
- ASPERA (NCT06823466)
- Where
- 47 sites in Croatia, Denmark and 13 more
- Volunteers
- 200 people
- Sponsor
- University of L'Aquila